Oral Factor D Inhibitor Compounds for Aberrant Complement Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inappropriate activation of the complement system leads to various disease pathologies affecting the immune, renal, cardiovascular, and neurological systems, necessitating the development of effective complement inhibitors for therapeutic treatment.
Innovation Solution
Development of compounds with specific structures, including arylene or heteroarylene rings, and pharmaceutically acceptable salts, to inhibit aberrant complement system activity, which are administered to treat conditions such as immunological disorders, neurodegenerative diseases, renal diseases, and cardiovascular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement activation is enhanced to improve pathogen destruction, then immune response effectiveness is improved, but harmful effects on healthy cells and tissue increase
Solution Approach 1:
The patent introduces complement factor D inhibitors as intermediary substances that selectively block the alternative pathway of complement activation. These inhibitors act as mediators between the immune system's need to destroy pathogens and the need to protect healthy tissues, preventing uncontrolled complement activation while preserving necessary immune function.
Solution Approach 2:
The patent modifies the activation parameters of the complement system by introducing compounds that specifically inhibit factor D activity. This changes the kinetic and threshold parameters of complement activation, raising the activation threshold to prevent inappropriate activation while maintaining the ability to respond to genuine threats through regulated pathways.
2Adaptability or versatility
If broad-spectrum complement inhibition is used to treat multiple diseases, then therapeutic versatility is improved, but specificity of treatment decreases
Solution Approach 1:
The patent develops complement factor D inhibitors with universal therapeutic application across multiple disease categories including immunological disorders, renal diseases, cardiovascular diseases, and neurological conditions. The single molecular entity addresses diverse pathologies through its fundamental role in regulating the alternative complement pathway, demonstrating multi-functionality.
Solution Approach 2:
While the inhibitor has broad applicability, the patent recognizes that different diseases require optimized dosing regimens and administration strategies. The local quality principle is applied by tailoring treatment parameters (dose, frequency, route of administration) to specific disease contexts while maintaining the same core therapeutic agent.
Data Source
AI summary
Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.